Resources

Articles, case studies, news, answers and downloads from Intrinsic Imaging's imaging core lab. Everything here is written by our physicians and staff, is open to read without a form, and is kept current as our work is published.

Press Releases and News

Trial awards, regulatory outcomes, certifications and company news from 2010 to today.

Press release

Intrinsic Imaging Announces Acquisition, Accelerating Global Expansion as a Leading Imaging Core Lab

September 1, 2026

Press release

Intrinsic Imaging Core Lab Announces its Acquisition for $80 Million

July 13, 2021

Press release

Intrinsic Imaging Undergoes Third FDA Inspection with No 483 Observations

March 1, 2021

All press releases

Guidance for Sponsors

Physician-written guidance on imaging endpoints, response criteria, acquisition and reader methodology, by therapeutic area.

Illustration of the human torso showing the heart and major blood vessels in red and blue

Guidance for Sponsors

Guidance for Sponsors · Volume 6, Issue 10 · 2026 Edition

Inferior Vena Cava Filters: Medical Imaging in Clinical Trials

By John Stoll, M.D.

October 17, 2026

Venous thromboembolism affects as many as 900,000 Americans each year and causes an estimated 60,000 to 100,000 deaths.[1] Anticoagulation is the treatment, but for patients who cannot be anticoagulated, an inferior vena cava (IVC) filter offers mechanical protection against pulmonary embolism. Filter use expanded dramatically with the introduction of retrievable devices, then came under scrutiny when the FDA warned of fractures, migration and perforation and when randomized evidence failed to show benefit in patients who could receive anticoagulation. Since then a large prospective trial has defined the safety of modern filters, professional societies have issued evidence-based guidelines and imaging has become central to both the indication for a filter and its follow-up. This issue reviews the evidence and the imaging a filter trial requires.

Read the article

Illustration of the liver with a white tumor on its surface against a dark background

Guidance for Sponsors

Guidance for Sponsors · Volume 6, Issue 9 · 2026 Edition

WHO, RECIST, EASL, mRECIST and Cheson: Challenges of Evaluating Tumor Response

By Patrick Middlebrook, M.D.

October 17, 2026

More than 100 therapeutic antibodies and a steady stream of small molecules, antibody-drug conjugates and immunotherapies have reached the market since the first monoclonal antibody was approved in 1986.[1] Nearly every one of them was judged, at least in part, by how tumors on imaging responded. The criteria used to make that judgment have evolved from the WHO handbook of 1981 through RECIST, its 2009 revision, immune-specific criteria, liver-specific criteria for hepatocellular carcinoma and the PET-based Lugano classification for lymphoma. Each was created to fix a weakness in its predecessor, and each has limitations of its own. This issue traces that evolution and offers practical guidance on choosing and applying criteria in a trial.

Read the article

Illustration of the colon with a red tumor mass in the sigmoid region representing colorectal cancer

Guidance for Sponsors

Guidance for Sponsors · Volume 6, Issue 8 · 2026 Edition

Metastatic Colorectal Cancer and Locoregional Therapies

By Patrick Middlebrook, M.D. and Hemant Mehta, M.D.

October 17, 2026

The American Cancer Society estimates about 158,850 new cases of colorectal cancer and 55,230 deaths in the United States in 2026, and the disease is now the leading cause of cancer death in adults under 50.[1] Roughly half of patients develop liver metastases, and for most of them the liver is what determines survival. Over the past decade the options for treating those metastases have multiplied: systemic therapy guided by molecular profiling, radioembolization, chemoembolization with drug-eluting beads, thermal ablation and, remarkably, liver transplantation. Each produces imaging changes that conventional size-based criteria handle poorly. This issue reviews the current evidence and what sponsors should build into trials of liver-directed therapy.

Read the article

All Guidance for Sponsors articles

Case Studies

Seventy-eight imaging core lab case studies across oncology, AI/CAD, medical devices, cardiovascular, CNS, gastroenterology, musculoskeletal and ophthalmology trials.

AI/CAD

Case study